Relationship of faecal calprotectin and long-term outcomes in Finnish patients with Crohn's disease: retrospective multi-centre chart review study.

Relationship of faecal calprotectin and long-term outcomes in Finnish patients with Crohn's disease: retrospective multi-centre chart review study. Scand J Gastroenterol. 2019 Sep 18;:1-7 Authors: Af Björkesten CG, Jussila A, Kemppainen H, Hallinen T, Soini E, Mankinen P, Valgarðsson S, Veckman V, Nissinen R, Naessens D, Molander P Abstract Background and Aims: A retrospective non-interventional, multi-centre patient chart review study was conducted to investigate the association of faecal calprotectin (FC) 1 year (±2 months) after biological therapy initiation with composite event-free survival (CEFS) consisting of surgical procedures, corticosteroid initiation, treatment failure or dose increase in patients with Crohn's disease (CD). In addition, the correlations of FC and other tests of disease activity were assessed. Materials and methods: Data on Finnish CD patients initiating a biological therapy between 2010 and 2016, were collected. The association of FC and CEFS was analysed with Kaplan-Meier and Cox proportional hazard modelling. The correlations were tested with Pearson's test. Results: Biological therapy was initiated in 186 patients, of which 87 (46.8%) had FC results available at 1 year and 80 had follow-up exceeding 14 months. The characteristics of patients with and without FC results were similar. Patients with elevated FC (>250 µg/g) had a significantly increased risk of experiencing c...
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research

Related Links:

Conclusion: UST showed to be effective and persistent, inducing short-term clinical benefit and endoscopic response in this real-life nationwide study of CD patients. Significant corticosteroid tapering in patients with highly treatment refractory and long-standing CD was observed. PMID: 31184512 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
This study showed a good safety and tolerability profile of the studied substance (Monteleone et al., 2012). Since TGFβ has been described to induce the profibrogenetic response of fibroblasts, patients were monitored for 6 months with intestinal ultrasonography, not showing signs of intestinal stenosis. Moreover, half of the patients maintained remission during the 6 months follow up period (Zorzi et al., 2012). Afterwards, a randomized, double-blind, phase 2 study was conducted in CD patients with inflammatory lesions in the terminal ileum and/or right colon, with steroid-dependence/resistance, randomized to three ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Noymar Luque-Campos1, Rafael A. Contreras-López1, María Jose Paredes-Martínez1, Maria Jose Torres2, Sarah Bahraoui3, Mingxing Wei4, Francisco Espinoza5, Farida Djouad3*, Roberto Javier Elizondo-Vega6* and Patricia Luz-Crawford1* 1Laboratorio de Inmunología Celular y Molecular, Centro de Investigación Biomédica, Facultad de Medicina, Universidad de los Andes, Santiago, Chile 2Escuela de Ingeniería Bioquímica, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile 3IRMB, INSERM, Univ Montpellier, Montpellier, France 4Cellvax, SAS...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusions We found that a significant proportion of IBD patients with AVN are reported in their records as having hip or low-back pain, and review of CT imaging under dedicated bone windows may identify AVN among this population. Our findings also suggest that additional etiological factors, beyond corticosteroids, contribute to the development of AVN in IBD. Further investigation is warranted regarding the mechanisms associated with AVN in IBD.
Source: JCR: Journal of Clinical Rheumatology - Category: Rheumatology Tags: Original Articles Source Type: research
DiscussionPrednisone and adalimumab are often used in the treatment of CD, resulting in a low incidence of osteonecrosis. Infection resulting from immunosuppression is one of the side effects of adalimumab. The relationship between corticosteroid use and osteonecrosis still needs investigation. Patients with CD and a history of steroid or immunosuppressive drug use should to be observed for osteonecrotic lesions of the jaw, mainly after dental procedures.
Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology - Category: ENT & OMF Source Type: research
Conclusion :HL can emerge in IBD patients on immunosuppressive therapy and physicians must be aware of this possibility. EBV infection might have an intermediate role between immunosuppressive treatment and lymphoma. Those data should alert clinicians that, not only thiopurine use but also the disease itself could contribute to a higher occurrence of lymphoproliferative disorders.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - Category: Hematology Authors: Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies Source Type: research
CONCLUSION: Patients with CD treated with golimumab were a treatment-refractory group. Despite this, more than one-third of the patients appeared to have had clinical benefit after a median follow-up of more than 1.5 years. PMID: 30353751 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
CONCLUSIONS: Initial IFX therapy for pouch inflammatory conditions is associated with IFX failure in just over half of all patients. Despite a high failure rate, an ileostomy can be avoided in almost three-quarters of patients at four years by using other medical therapies. PMID: 30270685 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
Conclusions: The Choosing Wisely recommendations will foster patient–physician discussions to optimize IBD therapy, reduce adverse effects from testing and treatment, and reduce medical expenditure.
Source: Inflammatory Bowel Diseases - Category: Gastroenterology Tags: IBD LIVE Articles Source Type: research
This study tests the hypothesis that measurements of faecal calprotectin (FCAL) pre- and post-anti-TNFα induction can predict primary non-response. METHODS: Retrospective study of 32 CD patients treated over a two-year period. Outcomes were assessed at 6 months based on clinical activity scores and the use of corticosteroids: (a) remission: Harvey-Bradshaw index (HBI) 2 months; (b) response: drop in HBI>3, off corticosteroids; (c) non-response: ΔFCAL (and ΔCRP, respectively) was calculated as (FCAL post-induction - FCAL pre-induction) × 100/FCAL pre induction. ...
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
More News: Corticosteroid Therapy | Crohn's Disease | Finland Health | Gastroenterology | Inflammatory Bowel Disease | PET Scan | Study